Avidity Biosciences, Inc

Avidity Biosciences, Inc. is a biopharmaceutical company focused on delivering RNA therapeutics known as antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases that were previously untreatable with such therapeutics. The pipeline includes three clinical-stage programs: Delpacibart zotadirsen in a Phase 2 open-label extension study (EXPLORE44) for Duchenne muscular dystrophy; Delpacibart etedesiran in Phase 3 for myotonic dystrophy type 1; and Delpacibart braxlosiran in Phase 1/2 for facioscapulohumeral muscular dystrophy. The company is also developing precision cardiology candidates for rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Incorporated in 2012 and headquartered in San Diego, California, Avidity Biosciences, Inc. operates as a subsidiary of Novartis AG as of February 27, 2026.